Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Howard Trachtman, M.D.
NYU School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- General Teaching Hospital Prague
Prague, Czechia
- Azienda Ospedaliero Universitaria Policlinico Di Bari
Bari, Italy
- Azienda Ospedaliero Universitaria Careggi
Florence, Italy
- Irccs Istituti Clinici Maugeri
Pavia, Italy
- Fondazione Policlinico Universitario Agostino Gemelli Irccs
Rome, Italy
- Balboa Nephrology Medical Group
San Diego, California, United States
- Los Angeles Biomedical Research Institute
Torrance, California, United States
- Colorado Kidney Care
Denver, Colorado, United States
- Miami Children'S Hospital
Miami, Florida, United States
- University of Miami Miller School of Medicine
Miami, Florida, United States
- University of Iowa Children'S Hospital
Iowa City, Iowa, United States
- Renal and Transplant Associates of New England, Pc
Springfield, Massachusetts, United States
- University of Minnesota
Minneapolis, Minnesota, United States
- the Children'S Mercy Hospital
Kansas City, Missouri, United States
- Columbia University Medical Center
New York, New York, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- Nyu Langone Medical Center
New York, New York, United States
- Suny Stony Brook Hospital
Stony Brook, New York, United States
- Unc Kidney Center, Pediatrics
Chapel Hill, North Carolina, United States
- University North Carolina (unc) Kidney Center
Chapel Hill, North Carolina, United States
- Akron Nephrology Associates
Akron, Ohio, United States
- the Cleveland Clinic Foundation
Cleveland, Ohio, United States
- Unversity of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- Northeast Clinical Research Center
Bethlehem, Pennsylvania, United States
- Temple University School of Medicine
Philadelphia, Pennsylvania, United States
- the Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
- University of Pennsylvania, Perelman School of Medicine
Philadelphia, Pennsylvania, United States
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
- Clinical Advancement Center
San Antonio, Texas, United States
- Southern Utah Kidney and Hypertension Center
St. George, Utah, United States
- University of Washington
Seattle, Washington, United States
- Catholic Health Initiatives Franciscan
Tacoma, Washington, United States
- Marshfield Clinic Research Foundation
Marshfield, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2014
- Primary completion
- 30 Jun 2016
- Completion
- 25 Mar 2024
- Last update posted
- 15 May 2025
- Registered enrollment
- 109
- Registry id
- NCT01613118
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.